Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys

• Published in: Virology (New York, N.Y.) Vol. 407; no. 1; pp. 1 - 6
• Main Authors: Ersching, Jonatan, Hernandez, Malva I.M., Cezarotto, Fabrizzio S., Ferreira, Jovino D.S., Martins, Amely B., Switzer, William M., Xiang, Zhiquan, Ertl, Hildegund C.J., Zanetti, Carlos R., Pinto, Aguinaldo R.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 10.11.2010
• Subjects: Adenoviridae Infections - immunology; Adenoviridae Infections - veterinary; Adenovirus; Adenoviruses, Human - immunology; Adenoviruses, Simian - immunology; Adolescent; Adult; Aged; Animals; Antibodies, Neutralizing - blood; Antibodies, Viral - blood; Brazil; Female; Human adenovirus; Humans; Infectious Disease; Male; Middle Aged; Neutralizing antibody; Platyrrhini; Primate Diseases - immunology; Primate Diseases - virology; Seroepidemiologic Studies; Seroneutralization assay; Simian adenovirus; Vaccines; Young Adult; Brazil; Simian adenovirus; Vaccines; Seroneutralization assay; Human adenovirus; Neutralizing antibody
• ISSN: 0042-6822; 1096-0341; 1096-0341
• DOI: 10.1016/j.virol.2010.07.043

Vaccines based on adenovirus (Ad) vectors are currently in development against several pathogens. However, neutralizing antibodies (NAb) to human adenovirus type 5 (AdHu5), the best-studied vector, are highly prevalent in humans worldwide. Less-prevalent adenoviruses, including human and simian serotypes, provide alternative vaccine platforms. In this study, sera from 200 Brazilian human subjects and New-World monkeys were tested for NAb titers to human serotypes AdHu5 and AdHu26 and chimpanzee-origin Ad viruses of serotype 6 (AdC6) and serotype 68 (AdC68). Seroprevalence rates of NAb in humans were 69.5% for AdHu5, 44% for AdHu26, 21% for AdC6 and 23.5% for AdC68. In addition, NAb titers to human Ad were consistently higher than those found to simian serotypes. Surprisingly, sera from some New-World monkey species were able to neutralize AdC6 and/or AdC68. A possible explanation for these findings and the implications for the development of Ad-vector vaccines are discussed in detail.